CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer (Grand Rounds)

Format: Webinar
Credit(s): 1.00 (60 min)
Webinar Date(s):
October 12, 2022 12:00 - 1:00 PM ET
October 18, 2022 12:00 - 1:00 PM ET
October 26, 2022 12:00 - 1:00 PM ET
Credit Type(s):
  • Physicians – AMA PRA Category 1 Credit(s) ™
  • Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

The introduction of CDK4/6 inhibitors into the treatment of HR-positive, HER2-negative metastatic breast cancer (mBC) resulted in a paradigm shift, and these agents are now considered the gold standard for first-line treatment. Since their approval, robust real-world data have been collected on the safety and efficacy of these agents outside the confines of a clinical trial. This includes new information on optimal selection between CDK4/6 inhibitors based on patient and disease characteristics and how best to sequence treatments across multiple lines of therapy.

This activity, CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer, will provide oncology practitioners with up-to-date information on the use of CDK4/6 inhibitors in the treatment of patients with HR-positive, HER2-negative mBC, including an in-depth evaluation of current clinical trial data and real-world experience with available CDK4/6 inhibitors and strategies for developing personalized patient treatment plans that take into consideration patient and disease characteristics such as comorbidities, menopausal status, and site of metastasis.

PROVIDER

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an educational grant from Novartis Pharmaceuticals Corporation.

RELATED COURSES

Advances in Cancer Screening and Detection: What PCPs Need to Know

Learn More

Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy

Learn More

Cardiovascular Risk Reduction in T2DM: Applying Trial Data in Cardiology Practice

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy